Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interferon stimulated exonuclease gene 20-like 2 (ISG20L2)
- Target
- ISG20L2
- Molecular classification
- Enzyme, Exoribonuclease, RNA processing factor, Other (not a receptor, kinase, transporter, GPCR, etc.)
01
Overview
Interferon stimulated exonuclease gene 20-like 2 (ISG20L2) is a 3'-5' exoribonuclease involved in the processing and maturation of ribosomal RNA (rRNA), specifically in ribosome biogenesis and the processing of 12S pre-rRNA[4]. It is part of a family of exonucleases that includes ISG20 (interferon-stimulated gene 20). ISG20L2 is structurally and functionally distinct from ISG20: whereas ISG20 is primarily known for its antiviral activity and interferon induction, ISG20L2 appears to play a more central role in cellular RNA metabolism rather than immune defense. There is limited data regarding its disease associations or clinical relevance as a direct therapeutic target. ISG20L2 does not currently have an established role in drug response, nor is it a clinically used biomarker or a common therapeutic target. If your intention was to find information on ISG20 (the canonical interferon-stimulated exonuclease with a strong role in immunity and antiviral responses), please clarify, as ISG20 and ISG20L2, while related, are distinct proteins with different functions[1][4].
- Other names
- ISG20L2Interferon stimulated gene 20-like 23’-5’ exoribonuclease ISG20L2ISG20L2 protein
02
Mechanism of action
Not applicable; there are no drugs known to act directly on ISG20L2.
03
Biological functions
Ribosome biogenesisrRNA processing (processing of 12S pre-rRNA)RNA metabolism
04
Disease associations
Limited information available; not directly characterized as a disease target. No strong direct association with specific pathologies or biomarker status found in current literature, unlike ISG20 which is associated with viral infection and immune response
05
Safety considerations
None reported (lack of clinical drug targeting or therapeutic use; no major toxicities or adverse effect profiles known for ISG20L2).
06
Interacting drugs
None known; no established drugs interact directly with ISG20L2 as a primary molecular target.
07
Biomarkers
None reported for ISG20L2 (ISG20, a related exonuclease, is considered an interferon response marker, but ISG20L2 is not explicitly cited as a biomarker[1]).
Beyond the preview
Go deeper on Interferon stimulated exonuclease gene 20-like 2 (ISG20L2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interferon stimulated exonuclease gene 20-like 2 (ISG20L2).